Search

Your search keyword '"Popov, Todor"' showing total 139 results

Search Constraints

Start Over You searched for: Author "Popov, Todor" Remove constraint Author: "Popov, Todor" Publication Year Range Last 3 years Remove constraint Publication Year Range: Last 3 years
139 results on '"Popov, Todor"'

Search Results

2. Perceptions of the impact of individual allergic rhinitis symptoms: A survey of ARIA clinical experts

Catalog

Books, media, physical & digital resources

3. Concepts for the Development of Person-Centered, Digitally Enabled, Artificial Intelligence–Assisted ARIA Care Pathways (ARIA 2024)

4. Exploring Definitions and Predictors of Response to Biologics for Severe Asthma

5. Definition, acronyms, nomenclature, and classification of angioedema (DANCE): AAAAI, ACAAI, ACARE, and APAAACI DANCE consensus

6. International Variation in Severe Exacerbation Rates in Patients With Severe Asthma

7. Impact of pre-biologic impairment on meeting domain-specific biologic responder definitions in patients with severe asthma

8. Analysis of comorbidities and multimorbidity in adult patients in the International Severe Asthma Registry

9. Urticaria exacerbations and adverse reactions in patients with chronic urticaria receiving COVID-19 vaccination: Results of the UCARE COVAC-CU study

10. Impact of Initiating Biologics in Patients With Severe Asthma on Long-Term Oral Corticosteroids or Frequent Rescue Steroids (GLITTER): Data From the International Severe Asthma Registry

12. Global Variability in Administrative Approval Prescription Criteria for Biologic Therapy in Severe Asthma

13. A Critical Review on microRNAs as Prognostic Biomarkers in Laryngeal Carcinoma.

18. Reply to “Exploring the long-term effects of biologic initiation in severe asthma: Insights from the International Severe Asthma Registry”

19. Real-world biologics response and super-response in the International Severe Asthma Registry cohort

20. Association between pre-biologic T2-biomarker combinations and response to biologics in patients with severe asthma

21. Impact of pre-biologic impairment on meeting domain-specific biologic responder definitions in patients with severe asthma

22. Association Between T2-related Comorbidities and Effectiveness of Biologics in Severe Asthma

24. Clinical remission following biologic initiation in severe asthma: results of the International Severe Asthma Registry (ISAR)

25. Real-world associations between outcomes and biomarkers in severe asthma patients treated with biologics

26. Real world biologic treatment response in severe asthma: an analysis of the International Severe Asthma Registry (ISAR)

27. Characteristics associated with clinical remission in patients with severe asthma who initiate biologics

28. Peritumor Mucosa in Advanced Laryngeal Carcinoma Exhibits an Aberrant Proangiogenic Signature Distinctive from the Expression Pattern in Adjacent Tumor Tissue.

29. Landau Levels versus Hydrogen Atom.

31. Impact of Inititing Biologics in Patients With Severe Asthma on Long-term Oral Corticosteroids or Frequent Rescue Steroids (GLITTER):Data From the International Severe Asthma Registry

32. Comparative effectiveness of anti-IL5 and anti-IgE biologic classes in patients with severe asthma eligible for both

33. Diabetes insipidus and Guillain-Barré-like syndrome following CAR-T cell therapy: a case report

34. Urticaria exacerbations and adverse reactions in patients with chronic urticaria receiving COVID-19 vaccination:Results of the UCARE COVAC-CU study

35. Comparative effectiveness of anti‐IL5 and anti‐IgE biologic classes in patients with severe asthma eligible for both

39. Comparative effectiveness of Anti-IL5 and Anti-IgE biologic classes in severe asthma patients eligible for both

40. Characterization of Patients in the International Severe Asthma Registry with High Steroid Exposure Who Did or Did Not Initiate Biologic Therapy

41. Solutions with exponential singularity for (3+1)-D Protter problems.

42. The Allergen Immunotherapy Adverse Events Registry: Setup & methodology of a European Academy of Allergy and Clinical Immunology taskforce project.

43. Adverse events in children and adolescents undergoing allergen immunotherapy for respiratory allergies—Report from the Allergen Immunotherapy Adverse Events Registry (ADER), a European Academy of Allergy and Clinical Immunology taskforce.

46. Characterization of Patients in the International Severe Asthma Registry with High Steroid Exposure Who Did or Did Not Initiate Biologic Therapy

47. Characterization of Patients in the International Severe Asthma Registry with High Steroid Exposure Who Did or Did Not Initiate Biologic Therapy

48. Development and validation of the Food Allergy Severity Score

49. Development and validation of the Food Allergy Severity Score